Brought to you by 
Oncobiologics nets $32.5mm through IPO
16 May 2016
Executive Summary
Oncobiologics Inc. (biosimilars for immune conditions and cancer) netted $32.5mm through its initial public offering of 5.8mm units at $6. Each unit held one share, half of a Series A warrant (each whole warrant is good for one share at $6.60 for nine months) and half of a Series B warrant (each whole Series B warrant is good for one share at $8.50 for two years). The company filed in February and last month announced that it intended to sell 5mm shares at a range of $11-13.
Deal Industry
- Pharmaceuticals
- Services
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oncobiologics nets $32.5mm through IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice